Merck Hep C Drug Zepatier OK'd
This article was originally published in Scrip
Executive Summary
Merck & Co. gained the FDA's go-ahead on Jan. 28 to market Zepatier (elbasvir and grazoprevir) as a treatment for adults with chronic hepatitis C virus (HCV) genotypes (GTs) 1 or 4 infection, with or without ribavirin (RBV).
You may also be interested in...
Nearing Finish Line, HCV Race Focuses On Salvage Therapy
With few remaining unmet needs in hepatitis C, Gilead, Merck and AbbVie are focusing on tough-to-treat niches with their next-gen combination regimens, especially treatment-experienced patients who failed on prior direct-acting antiviral therapy. Merck also is studying injectable drug users in an effort to eradicate HCV entirely.
NICE Backs Hep C Drug Zepatier After Merck Offers Price Discount
UK HTA gives provisional backing to Merck’s once-daily fixed-dose hepatitis C combo Zepatier after the US drug maker offers an undisclosed price cut.
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.